NO301768B1 - Fremgangsmåte for fremstilling av et biologisk aktivt transformerende vekstfaktor type <beta> (TGF-<beta>)-lignende protein - Google Patents

Fremgangsmåte for fremstilling av et biologisk aktivt transformerende vekstfaktor type <beta> (TGF-<beta>)-lignende protein Download PDF

Info

Publication number: NO301768B1
Authority: NO; Norway
Prior art keywords: tgf; protein; dimeric; cells; buffer
Prior art date: 1989-12-06

Application number

NO905264A

Other languages

English (en)

Norwegian (no)

Other versions

NO905264D0 (no

NO905264L (no

Inventor

Nico Cerletti

Gary Kent Mcmaster

David Cox

Albert Schmitz

Bernd Meyhack

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-06

Filing date

1990-12-05

Publication date

1997-12-08

1990-12-05 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1990-12-05 Publication of NO905264D0 publication Critical patent/NO905264D0/no

1991-06-07 Publication of NO905264L publication Critical patent/NO905264L/no

1997-12-08 Publication of NO301768B1 publication Critical patent/NO301768B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 62
230000008569 process Effects 0.000 title claims abstract description 13
108090000623 proteins and genes Proteins 0.000 title claims description 110
102000004169 proteins and genes Human genes 0.000 title claims description 97
108010009583 Transforming Growth Factors Proteins 0.000 title claims description 8
102000009618 Transforming Growth Factors Human genes 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title description 17
238000004519 manufacturing process Methods 0.000 claims abstract description 9
108010008268 transforming growth factor type e Proteins 0.000 claims description 26
239000003599 detergent Substances 0.000 claims description 19
239000000178 monomer Substances 0.000 claims description 18
230000002829 reductive effect Effects 0.000 claims description 18
239000002904 solvent Substances 0.000 claims description 14
230000004071 biological effect Effects 0.000 claims description 13
102000014914 Carrier Proteins Human genes 0.000 claims description 12
108091008324 binding proteins Proteins 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 10
NOGLQXZIGOQIBD-UHFFFAOYSA-N 1-(dimethylazaniumyl)propane-1-sulfonate Chemical compound CCC(N(C)C)S(O)(=O)=O NOGLQXZIGOQIBD-UHFFFAOYSA-N 0.000 claims description 7
BBCZJRSZHIFFAB-UHFFFAOYSA-N 1-(dimethylamino)-2-hydroxypropane-1-sulfonic acid Chemical compound CC(O)C(N(C)C)S(O)(=O)=O BBCZJRSZHIFFAB-UHFFFAOYSA-N 0.000 claims description 6
108010024636 Glutathione Proteins 0.000 claims description 6
238000006471 dimerization reaction Methods 0.000 claims description 6
210000000988 bone and bone Anatomy 0.000 claims description 5
229960003180 glutathione Drugs 0.000 claims description 4
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 3
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 3
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 3
230000000921 morphogenic effect Effects 0.000 claims description 2
229940099352 cholate Drugs 0.000 claims 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 2
229940009976 deoxycholate Drugs 0.000 claims 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 abstract description 5
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 5
230000001225 therapeutic effect Effects 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 90
210000004027 cell Anatomy 0.000 description 79
239000000872 buffer Substances 0.000 description 50
208000027418 Wounds and injury Diseases 0.000 description 43
206010052428 Wound Diseases 0.000 description 42
239000000203 mixture Substances 0.000 description 42
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
241000588724 Escherichia coli Species 0.000 description 34
240000004808 Saccharomyces cerevisiae Species 0.000 description 34
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 34
239000013612 plasmid Substances 0.000 description 33
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
239000007983 Tris buffer Substances 0.000 description 25
229940024606 amino acid Drugs 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 24
150000001413 amino acids Chemical class 0.000 description 23
230000015572 biosynthetic process Effects 0.000 description 22
239000002299 complementary DNA Substances 0.000 description 22
108020004414 DNA Proteins 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
210000001519 tissue Anatomy 0.000 description 19
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
239000012634 fragment Substances 0.000 description 18
239000000243 solution Substances 0.000 description 17
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
239000000499 gel Substances 0.000 description 16
239000013598 vector Substances 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
230000000694 effects Effects 0.000 description 14
238000002955 isolation Methods 0.000 description 14
239000002609 medium Substances 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
239000008188 pellet Substances 0.000 description 13
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 12
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
230000035876 healing Effects 0.000 description 11
230000000813 microbial effect Effects 0.000 description 11
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 10
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000000463 material Substances 0.000 description 10
238000000746 purification Methods 0.000 description 10
238000005119 centrifugation Methods 0.000 description 9
210000002950 fibroblast Anatomy 0.000 description 9
238000004007 reversed phase HPLC Methods 0.000 description 9
239000006228 supernatant Substances 0.000 description 9
125000003396 thiol group Chemical group [H]S* 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000006378 damage Effects 0.000 description 8
230000012010 growth Effects 0.000 description 8
238000011534 incubation Methods 0.000 description 8
238000005259 measurement Methods 0.000 description 8
230000000699 topical effect Effects 0.000 description 8
230000029663 wound healing Effects 0.000 description 8
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
241000700159 Rattus Species 0.000 description 7
125000003275 alpha amino acid group Chemical group 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
235000018417 cysteine Nutrition 0.000 description 7
239000000902 placebo Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
238000000926 separation method Methods 0.000 description 7
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
229910019142 PO4 Inorganic materials 0.000 description 6
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
208000002847 Surgical Wound Diseases 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000000539 dimer Substances 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
239000012071 phase Substances 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
235000021317 phosphate Nutrition 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
239000001632 sodium acetate Substances 0.000 description 6
235000017281 sodium acetate Nutrition 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
239000012506 Sephacryl® Substances 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
230000012292 cell migration Effects 0.000 description 5
238000010276 construction Methods 0.000 description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
239000003398 denaturant Substances 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
239000000284 extract Substances 0.000 description 5
239000008103 glucose Substances 0.000 description 5
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
229960002885 histidine Drugs 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
239000008223 sterile water Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
102000002933 Thioredoxin Human genes 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
210000002808 connective tissue Anatomy 0.000 description 4
239000007862 dimeric product Substances 0.000 description 4
230000006698 induction Effects 0.000 description 4
229930027917 kanamycin Natural products 0.000 description 4
229960000318 kanamycin Drugs 0.000 description 4
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
229930182823 kanamycin A Natural products 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
244000005700 microbiome Species 0.000 description 4
238000004264 monolayer culture Methods 0.000 description 4
239000002674 ointment Substances 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
239000012679 serum free medium Substances 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
108060008226 thioredoxin Proteins 0.000 description 4
229940094937 thioredoxin Drugs 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
102000013563 Acid Phosphatase Human genes 0.000 description 3
108010051457 Acid Phosphatase Proteins 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
-1 CuCl2 Chemical class 0.000 description 3
102000012410 DNA Ligases Human genes 0.000 description 3
108010061982 DNA Ligases Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
206010063560 Excessive granulation tissue Diseases 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
208000004210 Pressure Ulcer Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000006664 bond formation reaction Methods 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
210000003855 cell nucleus Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
238000001514 detection method Methods 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
210000001126 granulation tissue Anatomy 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
229960000789 guanidine hydrochloride Drugs 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000003993 interaction Effects 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
150000003573 thiols Chemical group 0.000 description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
230000037314 wound repair Effects 0.000 description 3
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
206010011985 Decubitus ulcer Diseases 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
102400001368 Epidermal growth factor Human genes 0.000 description 2
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
108010053070 Glutathione Disulfide Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920001612 Hydroxyethyl starch Polymers 0.000 description 2
206010020649 Hyperkeratosis Diseases 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000702208 Shigella phage SfX Species 0.000 description 2
239000008051 TBE buffer Substances 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
239000002585 base Substances 0.000 description 2
239000011324 bead Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000022159 cartilage development Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000032823 cell division Effects 0.000 description 2
108091092356 cellular DNA Proteins 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
230000003399 chemotactic effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000008602 contraction Effects 0.000 description 2
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
150000001945 cysteines Chemical class 0.000 description 2
229960003067 cystine Drugs 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000013024 dilution buffer Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
238000010828 elution Methods 0.000 description 2
108010003914 endoproteinase Asp-N Proteins 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
239000003630 growth substance Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
229940050526 hydroxyethylstarch Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000002513 implantation Methods 0.000 description 2
210000003000 inclusion body Anatomy 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000011572 manganese Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
230000011164 ossification Effects 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
230000020477 pH reduction Effects 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003223 protective agent Substances 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000004153 renaturation Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000034655 secondary growth Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000010265 sodium sulphite Nutrition 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
238000006277 sulfonation reaction Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
LZHOUAHZPZIFRR-VIFPVBQESA-N (2r)-2-amino-3-(2-pyridin-2-ylethylsulfanyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CSCCC1=CC=CC=N1 LZHOUAHZPZIFRR-VIFPVBQESA-N 0.000 description 1
150000004057 1,4-benzoquinones Chemical class 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical class C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
206010006802 Burns second degree Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
235000019750 Crude protein Nutrition 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241000702189 Escherichia virus Mu Species 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
101150009006 HIS3 gene Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241001622557 Hesperia Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
206010022714 Intestinal ulcer Diseases 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
241000589538 Pseudomonas fragi Species 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
101150001535 SRC gene Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000011759 adipose tissue development Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
239000010951 brass Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000000006 cell growth inhibition assay Methods 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000037319 collagen production Effects 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Inorganic materials [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
229940099500 cystamine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000053925 human CSF1 Human genes 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000006028 immune-suppresssive effect Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000001573 invertase Substances 0.000 description 1
235000011073 invertase Nutrition 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
101150054342 ner gene Proteins 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000010915 one-step procedure Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001151 other effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
238000012510 peptide mapping method Methods 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108010064037 prorennin Proteins 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108020003519 protein disulfide isomerase Proteins 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
125000002577 pseudohalo group Chemical group 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000007100 recyclization reaction Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000004911 serous fluid Anatomy 0.000 description 1
230000022379 skeletal muscle tissue development Effects 0.000 description 1
239000002893 slag Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
239000000606 toothpaste Substances 0.000 description 1
229940034610 toothpaste Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
108020005087 unfolded proteins Proteins 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Crystallography & Structural Chemistry (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Transplantation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO905264A 1989-12-06 1990-12-05 Fremgangsmåte for fremstilling av et biologisk aktivt transformerende vekstfaktor type <beta> (TGF-<beta>)-lignende protein NO301768B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898927546A GB8927546D0 (en)	1989-12-06	1989-12-06	Process for the production of biologically active tgf-beta

Publications (3)

Publication Number	Publication Date
NO905264D0 NO905264D0 (no)	1990-12-05
NO905264L NO905264L (no)	1991-06-07
NO301768B1 true NO301768B1 (no)	1997-12-08

Family

ID=10667491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO905264A NO301768B1 (no)	1989-12-06	1990-12-05	Fremgangsmåte for fremstilling av et biologisk aktivt transformerende vekstfaktor type <beta> (TGF-<beta>)-lignende protein

Country Status (23)

Country	Link
US (2)	US5650494A (fi)
EP (2)	EP0433225B1 (fi)
JP (1)	JP3048061B2 (fi)
KR (1)	KR100203230B1 (fi)
AT (1)	ATE178616T1 (fi)
AU (1)	AU638075B2 (fi)
CA (1)	CA2031430C (fi)
DE (1)	DE69033040T2 (fi)
DK (1)	DK0433225T3 (fi)
ES (1)	ES2132066T3 (fi)
FI (1)	FI103278B (fi)
GB (1)	GB8927546D0 (fi)
GR (1)	GR3030703T3 (fi)
HU (1)	HU218144B (fi)
IE (2)	IE904386A1 (fi)
IL (1)	IL96549A (fi)
MX (1)	MX172600B (fi)
NO (1)	NO301768B1 (fi)
NZ (1)	NZ236333A (fi)
PH (1)	PH31649A (fi)
PT (1)	PT96068B (fi)
SG (1)	SG52690A1 (fi)
ZA (1)	ZA909762B (fi)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150328A (en) *	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
EP0547102B1 (en) *	1990-09-05	1998-07-08	Southern Cross Biotech Pty.Ltd.	Solubilization of proteins in active forms
GB9106678D0 (en) *	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing
US20080139474A1 (en) *	1991-11-04	2008-06-12	David Israel	Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
ATE238417T1 (de)	1991-11-04	2003-05-15	Inst Genetics Llc	Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
AU2738392A (en) *	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors
US5288931A (en) *	1991-12-06	1994-02-22	Genentech, Inc.	Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9206861D0 (en)	1992-03-28	1992-05-13	Univ Manchester	Wound healing and treatment of fibrotic disorders
US6884787B2 (en) *	2001-07-14	2005-04-26	Isis Pharmaceuticals, Inc.	Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) *	1992-12-23	1994-06-30	Behringwerke Ag	Verfahren zur Reaktivierung von gereinigten Membranproteinen
AU5955294A (en) *	1993-01-08	1994-08-15	Upjohn Company, The	Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
WO1994025588A2 (en)	1993-04-30	1994-11-10	Biognostik Gesellschaft für Biomolekulare Diagnostik mbH	ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
US5663304A (en) *	1993-08-20	1997-09-02	Genentech, Inc.	Refolding of misfolded insulin-like growth factor-I
AU7846894A (en) *	1993-09-29	1995-04-18	Alcon Laboratories, Inc.	Compositions containing growth factors and antiplastic agents
US5411940A (en) *	1993-09-29	1995-05-02	Alcon Laboratories, Inc.	Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
US5399677A (en) *	1993-12-07	1995-03-21	Genetics Institute, Inc.	Mutants of bone morphogenetic proteins
PT733109E (pt) *	1993-12-07	2006-07-31	Genetics Inst Llc	Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao
US6027919A (en)	1993-12-07	2000-02-22	Genetics Institute, Inc.	BMP-12 and BMP-13 proteins and DNA encoding them
TW440566B (en) *	1994-07-25	2001-06-16	Novartis Ag	Novel process for the production of biologically active dimeric protein
WO1996003425A1 (en) *	1994-07-25	1996-02-08	Ciba-Geigy Ag	Process for folding of proteins like recombinant hirudin or epidermal growth factor
TW517059B (en)	1994-07-25	2003-01-11	Ciba Geigy Ag	New process for the production of biologically active protein
WO1996033215A1 (fr)	1995-04-19	1996-10-24	Hoechst Pharmaceuticals & Chemicals K.K.	Proteine nouvelle et son procede de fabrication
US5714371A (en) *	1995-05-12	1998-02-03	Schering Corporation	Method for refolding insoluble aggregates of hepatitis C virus protease
US5800811A (en) *	1995-06-06	1998-09-01	Hall; Frederick L.	Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6352972B1 (en) *	1995-06-06	2002-03-05	Marcel E. Nimni	Bone morphogenetic proteins and their use in bone growth
US6040431A (en)	1995-06-07	2000-03-21	Stryker Corporation	Single chain analogs of the TGF-β superfamily (morphons)
CA2235223A1 (en)	1995-10-30	1997-05-09	Massachusetts Institute Of Technology	Rationally designed polysaccharide lyases derived from heparinase i
WO1997023638A1 (fr) *	1995-12-21	1997-07-03	Ajinomoto Co., Inc.	Procede pour replier l'activine a humaine
US20030185792A1 (en) *	1996-01-22	2003-10-02	Curis, Inc.	Morphogen analogs of bone morphogenic proteins
CA2244228A1 (en) *	1996-01-22	1997-07-24	Creative Biomolecules, Inc.	Morphogen analogs and methods for producing them
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en)	1996-12-25	2010-10-12	Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	Process for preparing purified active monomer of bone-derived factor
US6500920B1 (en) *	1997-06-19	2002-12-31	St. Louis University	Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
US7723473B2 (en)	1997-06-19	2010-05-25	St. Louis University	Peptide antagonists of TGF-beta family members and therapeutic uses thereof
ATE220564T1 (de)	1997-08-14	2002-08-15	Sulzer Innotec Ag	Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
US20020052026A1 (en) *	1997-10-08	2002-05-02	Steven M. Vicik	Methods of refolding proteins
DE19749259A1 (de) *	1997-11-07	1999-05-12	Dade Behring Marburg Gmbh	Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
ATE513042T1 (de) *	1998-02-05	2011-07-15	Glaxosmithkline Biolog Sa	Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
US6057128A (en)	1998-03-17	2000-05-02	Genetics Institute, Inc.	MU-1, member of the cytokine receptor family
FR2776521B1 (fr) *	1998-03-27	2000-12-15	Pf Medicament	Utilisation de conjugues p40 actifs par voie nasale
US7056504B1 (en)	1998-08-27	2006-06-06	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase I and II
US6933272B1 (en)	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
US6677432B1 (en)	1998-10-07	2004-01-13	Stryker Corporation	Mutations of the C-terminal portion of TGF-β superfamily proteins
JP3762222B2 (ja)	1998-10-07	2006-04-05	ストライカー・コーポレーション	改変型ＴＧＦ−βスーパーファミリータンパク質
US6846906B1 (en)	1998-10-07	2005-01-25	Stryker Corporation	Modified proteins of the TGF-β superfamily, including morphogenic proteins
US7087577B2 (en)	1998-10-16	2006-08-08	Zimmer Orthobiologies, Inc.	Method of promoting natural bypass
US6992066B2 (en)	1998-10-16	2006-01-31	Zimmer Orthobiologics, Inc.	Povidone-containing carriers for polypeptide growth factors
ES2146552B1 (es) *	1998-11-24	2001-04-16	Inst Cientifico Tecnol Navarra	Peptidos inhibidores de tgf/31
WO2000040610A1 (fr) *	1999-01-07	2000-07-13	Takeda Chemical Industries, Ltd.	Procede de production de proteines activees
US6727224B1 (en) *	1999-02-01	2004-04-27	Genetics Institute, Llc.	Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de)	1999-02-13	2000-08-17	Walter Sebald	Protein mit einem Heparin-bindenden Epitop
CA2643162C (en)	1999-04-23	2018-01-02	Massachusetts Institute Of Technology	Polymer identification, compositional analysis and sequencing, based on property comparison
DE19944626A1 (de) *	1999-09-17	2001-03-22	Knoell Hans Forschung Ev	Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
AU4351201A (en)	2000-03-08	2001-09-17	Massachusetts Inst Technology	Heparinase iii and uses thereof
DE10026713A1 (de) *	2000-05-30	2001-12-06	Walter Sebald	Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) *	2000-06-28	2006-07-25	Zimmer Orthobiologics, Inc.	Protein mixtures for wound healing
DK1319183T3 (da)	2000-09-12	2009-05-18	Massachusetts Inst Technology	Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
CA2423469A1 (en)	2000-10-18	2002-04-25	Massachusetts Institute Of Technology	Methods and products related to pulmonary delivery of polysaccharides
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
US7157557B2 (en)	2001-02-23	2007-01-02	Immunex Corporation	Increased recovery of active proteins
US7276580B2 (en)	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
DK1399023T3 (da) *	2001-06-01	2008-08-18	Wyeth Corp	Sammensætninger til systemisk indgivelse af sekvenser, der koder for knoglemorfogenese-proteiner
FI117667B (fi)	2001-07-05	2007-01-15	Univ Zuerich	Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CA2460916A1 (en)	2001-10-04	2003-04-10	Laura Carter	Methods and compositions for modulating interleukin-21 receptor activity
US7232802B2 (en)	2001-12-21	2007-06-19	Zimmer Orthobiologics, Inc.	Compositions and methods for promoting myocardial and peripheral angiogenesis
US7744862B2 (en) *	2002-02-05	2010-06-29	Geymonat S.P.A.	Production process of recombinant placental growth factor
US7622562B2 (en)	2002-06-26	2009-11-24	Zimmer Orthobiologics, Inc.	Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7241740B2 (en) *	2002-08-13	2007-07-10	Wyeth	Peptides as solubilizing excipients for transforming growth factor beta proteins
JP4571776B2 (ja) *	2002-11-05	2010-10-27	Ｊｘ日鉱日石エネルギー株式会社	潤滑油組成物
US7074412B2 (en)	2003-01-30	2006-07-11	The University Of Zurich	Pharmaceutical composition
US8163875B2 (en)	2003-04-18	2012-04-24	Biogen Idec Ma Inc.	Polymer conjugated glycosylated neublastin
BRPI0413720A (pt)	2003-09-12	2006-10-17	Wyeth Corp	bastões e pastas sólidas de fosfato de cálcio injetável para liberação de proteìnas osteogênicas
ES2367694T3 (es)	2003-12-11	2011-11-07	Isto Technologies Inc.	Sistema de cartílago particulado.
JP4852545B2 (ja) *	2004-08-19	2012-01-11	バイオジェン・アイデック・エムエイ・インコーポレイテッド	ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体
DE602005022082D1 (de) *	2004-08-19	2010-08-12	Biogen Idec Inc	Rückfaltung von proteinen der transforming-growth-factor-beta-familie
US20060166251A1 (en) *	2005-01-26	2006-07-27	Archambault Joanne M	Use of sFRPs as markers of BMP activity
AU2006214384A1 (en)	2005-02-14	2006-08-24	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of IL-17F in diagnosis and therapy of airway inflammation
AU2006214473A1 (en)	2005-02-14	2006-08-24	Wyeth	Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
CN101309698A (zh) *	2005-03-30	2008-11-19	惠氏公司	通过施用bmp来刺激毛发生长的方法
GT200600148A (es)	2005-04-14	2006-11-22		Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) *	2005-07-12	2005-08-17	Renovo Ltd	Promotion of epithelial regeneration
US20070021591A1 (en) *	2005-07-25	2007-01-25	Trubion Pharmaceuticals, Inc.	Compositions and methods for protein deaggregation
GB0516204D0 (en) *	2005-08-06	2005-09-14	Riotech Pharmaceuticals Ltd	Methods
EP1916964A4 (en)	2005-08-26	2015-11-04	Zimmer Inc	IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
WO2007103182A2 (en) *	2006-03-01	2007-09-13	Biogen Idec Ma Inc.	Compostions and methods for administering gdnf ligand family proteins
US7582609B2 (en) *	2006-03-01	2009-09-01	Digna Biotech, S.L.	Method for the treatment of skin fibrosis and suitable compositions for such treatment
GB0604938D0 (en)	2006-03-11	2006-04-19	Renovo Ltd	Proteins, nucleic acids and medicaments
GB0604966D0 (en) *	2006-03-11	2006-04-19	Renovo Ltd	Medicaments and proteins
GB0604964D0 (en)	2006-03-11	2006-04-19	Renovo Ltd	Protein folding
RU2439076C2 (ru) *	2006-07-14	2012-01-10	Дженентек, Инк.	Способ выделения повторно свернутого рекомбинантного белка из культуры прокариотических клеток (варианты)
GB0617816D0 (en) *	2006-09-11	2006-10-18	Renovo Ltd	Nucleic acids and methods of protein expression
RU2520810C2 (ru)	2006-11-08	2014-06-27	Вайет	Рационально разработанные среды для культивирования клеток
US8163549B2 (en)	2006-12-20	2012-04-24	Zimmer Orthobiologics, Inc.	Method of obtaining viable small tissue particles and use for tissue repair
US20090012629A1 (en)	2007-04-12	2009-01-08	Isto Technologies, Inc.	Compositions and methods for tissue repair
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
US8329655B2 (en) *	2007-05-01	2012-12-11	Biogen Idec Ma Inc.	Methods for increasing vascularization
US20110135648A1 (en) *	2007-08-08	2011-06-09	Biogen Idec Ma Inc.	Anti-neublastin antibodies and uses thereof
EP3327132A3 (en)	2007-08-09	2018-07-18	Wyeth LLC	Use of perfusion to enhance production of fed-batch cell culture in bioreactors
WO2009029656A1 (en)	2007-08-27	2009-03-05	Auxagen, Inc.	METHODS FOR INHIBITING TGF-β
US8487006B2 (en)	2008-09-16	2013-07-16	Auxagen, Inc.	Method of enhancing TGF-β signalling
US8494140B2 (en) *	2008-10-30	2013-07-23	Centurylink Intellectual Property Llc	System and method for voice activated provisioning of telecommunication services
US8058407B2 (en)	2008-10-31	2011-11-15	Wyeth Llc	Purification of acidic proteins using ceramic hydroxyapatite chromatography
MX2011013898A (es)	2009-06-22	2012-05-22	Amgen Inc	Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
WO2010151688A2 (en)	2009-06-25	2010-12-29	Amgen Inc.	Capture purification processes for proteins expressed in a non-mammalian system
KR100991203B1 (ko)	2010-05-10	2010-11-01	심영복	골형성 단백질의 정제 방법
JPWO2012029148A1 (ja)	2010-09-01	2013-10-28	株式会社オステオファーマ	組換えヒト骨形成タンパク質−２凍結乾燥製剤
EP2813211A4 (en) *	2012-02-10	2015-11-04	Japanic Corp	COSMETIC PRODUCT OR SKIN REGENERATION PROMOTING AGENT COMPRISING A NONHUMAN STEM CELL CULTURING SUPERTENANT AS A STARTING MATERIAL, AND METHOD FOR INTRODUCING IONS FOR PROTEINS
JP6465800B2 (ja)	2012-08-06	2019-02-06	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	エンベロープウイルスを不活化するための方法および組成物
US20140178343A1 (en)	2012-12-21	2014-06-26	Jian Q. Yao	Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
WO2018122794A1 (en)	2016-12-30	2018-07-05	Biogend Therapeutics Co., Ltd.	Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH16153A (en) *	1980-03-27	1983-07-12	Lilly Co Eli	Process for producing an insulin
GR79124B (fi) *	1982-12-22	1984-10-02	Genentech Inc
US4620948A (en) *	1982-12-22	1986-11-04	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
WO1984004924A1 (en) *	1983-06-03	1984-12-20	Us Commerce	Purified transforming growth factor-beta derived from human platelets and placentas
ATE85080T1 (de) *	1984-02-17	1993-02-15	Genentech Inc	Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4572798A (en) *	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) *	1985-02-22	1988-03-15	Monsanto Company	Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) *	1985-03-22	1991-07-18	Genentech Inc	Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) *	1985-03-29	1985-05-09	Creighton T E	Production of protein
EP0208539A3 (en) *	1985-07-11	1988-08-03	Repligen Corporation	Folding disulfide-cross-linkable proteins
US5453363A (en) *	1985-10-23	1995-09-26	Boehringer Mannheim Gmbh	Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) *	1986-10-20	1991-05-28	Oncogene Science Inc	Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
NZ222569A (en) *	1986-11-17	1990-08-28	Sandoz Ltd	Production of glioblastoma-derived t cell suppressor factor (g-tsf) using recombinant techniques
FI100106B (fi) *	1986-12-05	1997-09-30	Novartis Ag	Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) *	1987-01-30	1990-06-05	Techne Corporation	Heterodimer form of transforming growth factor-beta
US5013653A (en) *	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) *	1987-04-16	1993-03-15	Cetus Oncology Corp	Production of purified, biologically active, bacterially produced recombinant human csf-1
WO1988008849A1 (en) *	1987-05-11	1988-11-17	Cetus Corporation	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US5162507A (en) *	1987-05-11	1992-11-10	Cetus Corporation	Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
EP0293785A3 (en) *	1987-05-29	1990-05-02	Oncogen Limited Partnership	Cloning and expression of simian transforming growth factor-ss1
US4985544A (en) *	1987-08-04	1991-01-15	Kyowa Hakko Kogyo Co., Ltd.	Process for renaturing fish growth hormone
US5061786A (en) *	1989-05-25	1991-10-29	Genentech, Inc.	Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5144006A (en) *	1991-06-13	1992-09-01	The Rockefeller University	Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) *	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors

1989
- 1989-12-06 GB GB898927546A patent/GB8927546D0/en active Pending
1990
- 1990-11-27 DK DK90810922T patent/DK0433225T3/da active
- 1990-11-27 AT AT90810922T patent/ATE178616T1/de not_active IP Right Cessation
- 1990-11-27 DE DE69033040T patent/DE69033040T2/de not_active Expired - Lifetime
- 1990-11-27 ES ES90810922T patent/ES2132066T3/es not_active Expired - Lifetime
- 1990-11-27 EP EP90810922A patent/EP0433225B1/en not_active Expired - Lifetime
- 1990-11-27 SG SG1996007909A patent/SG52690A1/en unknown
- 1990-11-27 EP EP98113487A patent/EP0891985A1/en not_active Withdrawn
- 1990-11-27 AU AU67018/90A patent/AU638075B2/en not_active Expired
- 1990-11-30 JP JP2330871A patent/JP3048061B2/ja not_active Expired - Lifetime
- 1990-12-03 FI FI905956A patent/FI103278B/fi active IP Right Grant
- 1990-12-04 MX MX023579A patent/MX172600B/es unknown
- 1990-12-04 PT PT96068A patent/PT96068B/pt not_active IP Right Cessation
- 1990-12-04 NZ NZ236333A patent/NZ236333A/en unknown
- 1990-12-04 CA CA002031430A patent/CA2031430C/en not_active Expired - Lifetime
- 1990-12-05 IE IE438690A patent/IE904386A1/en not_active IP Right Cessation
- 1990-12-05 IL IL9654990A patent/IL96549A/xx not_active IP Right Cessation
- 1990-12-05 IE IE19990992A patent/IE990992A1/en not_active IP Right Cessation
- 1990-12-05 ZA ZA909762A patent/ZA909762B/xx unknown
- 1990-12-05 KR KR1019900019881A patent/KR100203230B1/ko not_active IP Right Cessation
- 1990-12-05 NO NO905264A patent/NO301768B1/no not_active IP Right Cessation
- 1990-12-05 HU HU084/90A patent/HU218144B/hu unknown
1994
- 1994-03-25 PH PH8001A patent/PH31649A/en unknown
1995
- 1995-06-07 US US08/486,057 patent/US5650494A/en not_active Expired - Lifetime
1997
- 1997-01-24 US US08/789,588 patent/US5922846A/en not_active Expired - Fee Related
1999
- 1999-07-07 GR GR990401786T patent/GR3030703T3/el unknown

Also Published As

Publication number	Publication date
US5922846A (en)	1999-07-13
NO905264D0 (no)	1990-12-05
MX172600B (es)	1994-01-03
CA2031430A1 (en)	1991-06-07
EP0891985A1 (en)	1999-01-20
PT96068A (pt)	1991-09-30
US5650494A (en)	1997-07-22
AU638075B2 (en)	1993-06-17
GB8927546D0 (en)	1990-02-07
CA2031430C (en)	2003-05-27
FI103278B1 (fi)	1999-05-31
IL96549A0 (en)	1991-09-16
IL96549A (en)	2000-10-31
IE990992A1 (en)	2000-12-13
EP0433225A1 (en)	1991-06-19
ZA909762B (en)	1991-08-28
FI905956A0 (fi)	1990-12-03
AU6701890A (en)	1991-06-13
PH31649A (en)	1999-01-12
KR100203230B1 (ko)	1999-06-15
SG52690A1 (en)	1998-09-28
PT96068B (pt)	1998-02-27
DE69033040D1 (de)	1999-05-12
GR3030703T3 (en)	1999-11-30
IE904386A1 (en)	1991-06-19
ATE178616T1 (de)	1999-04-15
ES2132066T3 (es)	1999-08-16
HU908084D0 (en)	1991-06-28
NO905264L (no)	1991-06-07
DE69033040T2 (de)	1999-09-09
NZ236333A (en)	1992-03-26
HUT56880A (en)	1991-10-28
FI103278B (fi)	1999-05-31
HU218144B (hu)	2000-06-28
KR910012240A (ko)	1991-08-07
JPH03191791A (ja)	1991-08-21
FI905956A (fi)	1991-06-07
EP0433225B1 (en)	1999-04-07
JP3048061B2 (ja)	2000-06-05
DK0433225T3 (da)	1999-10-25

Publication	Publication Date	Title
EP0433225B1 (en)	1999-04-07	Process for the production of biologically active protein (e.g. TGF)
JP4354980B2 (ja)	2009-10-28	生物学的に活性なタンパク質の製造のための新規の方法
JP2007031453A (ja)	2007-02-08	生物学的に活性な二量体型タンパク質の製造のための新規の方法
NZ245047A (en)	1995-04-27	Hybrid transforming growth factor and recombinant dna encoding such a hybrid
KR101022934B1 (ko)	2011-03-16	태반성장인자 타입 1 뮤테인의 제조방법 및 이의 사용방법

Legal Events

Date	Code	Title	Description
2010-12-27	MK1K	Patent expired